Clinical Trials

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Th

Cancer Type

Breast Cancer - In situ

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Virginia Kaklamani, MD

For more information about this study
View Details

About This Study

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumabwhen given in combination with trastuzumab emtansine compared with placebo andtrastuzumab emtansine for patients with residual invasive HER2-positive breast cancerfollowing neoadjuvant taxane-based and HER2-targeted therapy including trastuzumab, whoare at high risk of disease recurrence. The primary endpoint for this study is invasivedisease-free survival (IDFS).